Nielsen joins Catalent as chief technology officer
Catalent Pharma Solutions has appointed Kurt Nielsen as chief technology officer and senior vice president of innovation and growth.
Nielsen will drive innovation activities and investments across Catalent's range of advanced dose forms and packaging technologies. He will be based in Catalent's global headquarters in Somerset, NJ, US.
Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical Company, where he led new product development and licensing activities for both products and drug delivery technologies, as well as the division's manufacturing and quality operations.
Nielsen has also held r&d leadership positions with Teva Pharmaceuticals US and the McNeil Consumer Products division of Johnson & Johnson. He has a PhD in chemistry from Villanova University and a BSc in chemistry from the University of Delaware.
You may also like
Manufacturing
Expanded access and commercial packaging for niche-market drugs
Securing timely and reliable commercial packaging services can be challenging for orphan, niche and other low-volume drugs because of their need to compete against high-volume drugs for access to the limited and often preallocated production capacity available at contract packaging facilities. Catalent's Karl Jones and Matthew Stark report